At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 66 enrolled
Drug / intervention
ranibizumab +1 moredrug
Likely dose
ranibizumab 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab
In Brief
A Phase 3 clinical trial evaluating ranibizumab and Peripheral Laser for Retinal Vein Occlusion. Completed, enrolled 66 participants across 6 sites.
Detailed Summary
This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \& CRUISE trials and subsequently followed in the HORIZON extension trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion
CountriesUnited States
CollaboratorsThe Macula Foundation, Inc., Genentech, Inc.
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedSep 2010
Primary CompletionDec 2012
TodayJul 2026
First PostedSep 10, 2010
Enrollment StartAug 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.8 years ago
Interventions
ranibizumabdrug
Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
Peripheral Laserother
Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.